Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. ( HRMY ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Matthew Beck Jeffrey Dayno - President, CEO & Director Adam Zaeske - Executive VP & Chief Commercial Officer Kumar Budur - Executive VP and Chief Medical & Scientific Officer Sandip Kapadia - Executive VP, Chief Administrative Officer & CFO Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Hoang - Deutsche Bank AG, Research Division Presentation Operator Good morning.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a year ago.
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences Holdings, Inc. (HRMY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Harmony Biosciences Holdings, Inc. ever had a stock split?
Harmony Biosciences Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeffrey M. Dayno CEO | NASDAQ (NMS) Exchange | 413197104 CUSIP |
| US Country | 268 Employees | - Last Dividend | - Last Split | 19 Aug 2020 IPO Date |
Overview
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company dedicated to the development and commercialization of unique therapies for patients suffering from rare and other neurological diseases within the United States. Initially known as Harmony Biosciences II, Inc., the company underwent a name change to Harmony Biosciences Holdings, Inc. in February 2020. Founded in 2017, Harmony Biosciences has established its headquarters in Plymouth Meeting, Pennsylvania, signifying its commitment to addressing unmet medical needs in the neurology space through innovative research and therapeutic solutions.
Products and Services
- WAKIX (pitolisant)
- HBS-102
Harmony Biosciences offers WAKIX (pitolisant), which is a pioneering molecule known for its novel mechanism of action. It is specifically designed for the treatment of excessive daytime sleepiness in adult patients suffering from narcolepsy. This product marks a significant advancement in narcolepsy treatment, offering a new hope and improved quality of life for patients grappling with this chronic sleep disorder.
Another significant therapeutic solution in Harmony Biosciences' portfolio is HBS-102, which targets the melanin-concentrating hormone receptor 1 for MCH neurons. This product represents the company's ongoing commitment to exploring new pathways and mechanisms to address neurological disorders with unmet medical needs. While still under development, HBS-102 underscores Harmony Biosciences’ dedication to expanding its offerings and making impactful contributions to the field of neurology.
Contact Information
